The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.

ABSTRACT:

Purpose

Hormone receptor-positive/HER2-negative (HR⁺/HER2^-) breast cancer is associated with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1, and demonstrates poor responses to checkpoint inhibitor therapy. Evaluating the effect of standard chemotherapy on the immune microenvironment may suggest new opportunities for immunotherapy-based approaches to treating HR⁺/HER2^- breast tumors.

Experimental design

HR⁺/HER2^- breast tumors were analyzed before and after neoadjuvant chemotherapy. sTIL were assessed histologically; CD8⁺ cells, CD68⁺ cells, and PD-L1 staining were assessed immunohistochemically; whole transcriptome sequencing and panel RNA expression analysis (NanoS

SUBMITTER: Waks AG 

PROVIDER: S-EPMC6677598 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature